146 related articles for article (PubMed ID: 11774835)
1. Successful control of subfulminant hepatitis related to lamivudine-resistant hepatitis B virus in an HIV-infected patient.
Thabut D; Thibault V; Benhamou Y; Bernard B; Aubron-Olivier C; Poynard T; Di Martino V
AIDS; 2001 Dec; 15(18):2463-4. PubMed ID: 11774835
[No Abstract] [Full Text] [Related]
2. Lamivudine and famciclovir treatment in HIV patients with acute hepatitis B virus infection and hepatitis B reactivation.
Panos GZ; Lampropoulos KM; Angelousi AG; Charatsis GG; Falagas ME
J Clin Gastroenterol; 2007 Feb; 41(2):222-3. PubMed ID: 17245225
[No Abstract] [Full Text] [Related]
3. Oral ganciclovir for treatment of lamivudine-resistant hepatitis B virus infection: a pilot study.
Bozkaya H; Yurdaydin C; Bozdayi AM; Erkan O; Karayalcin S; Uzunalimoglu O
Clin Infect Dis; 2002 Oct; 35(8):960-5. PubMed ID: 12355383
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis B virus variants with lamivudine-related mutations in the DNA polymerase and the 'a' epitope of the surface antigen are sensitive to ganciclovir.
Oon CJ; Chen WN; Lim N; Koh S; Lim GK; Leong AL; Tan GS
Antiviral Res; 1999 Apr; 41(3):113-8. PubMed ID: 10320044
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients.
Benhamou Y; Dohin E; Lunel-Fabiani F; Poynard T; Huraux JM; Katlama C; Opolon P; Gentilini M
Lancet; 1995 Feb; 345(8946):396-7. PubMed ID: 7845151
[No Abstract] [Full Text] [Related]
6. Hepatitis B virus drug resistance in HIV-1-infected patients taking lamivudine-containing antiretroviral therapy.
Wongprasit P; Manosuthi W; Kiertiburanakul S; Sungkanuparph S
AIDS Patient Care STDS; 2010 Apr; 24(4):205-9. PubMed ID: 20377434
[TBL] [Abstract][Full Text] [Related]
7. Primary infection with a lamivudine-resistant hepatitis B virus.
Thibault V; Aubron-Olivier C; Agut H; Katlama C
AIDS; 2002 Jan; 16(1):131-3. PubMed ID: 11741175
[No Abstract] [Full Text] [Related]
8. Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study.
Benhamou Y; Bochet M; Thibault V; Calvez V; Fievet MH; Vig P; Gibbs CS; Brosgart C; Fry J; Namini H; Katlama C; Poynard T
Lancet; 2001 Sep; 358(9283):718-23. PubMed ID: 11551579
[TBL] [Abstract][Full Text] [Related]
9. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus.
Benhamou Y; Tubiana R; Thibault V
N Engl J Med; 2003 Jan; 348(2):177-8. PubMed ID: 12519935
[No Abstract] [Full Text] [Related]
10. Reactivation of lamivudine-resistant occult hepatitis B in an HIV-infected patient undergoing cytotoxic chemotherapy.
Schnepf N; Sellier P; Bendenoun M; Zini JM; Sanson-le Pors MJ; Mazeron MC
J Clin Virol; 2007 May; 39(1):48-50. PubMed ID: 17368969
[TBL] [Abstract][Full Text] [Related]
11. [Advance in clinical studies of the kinetics of hepatitis B virus].
Tang YT; Cao Q; Zhang DZ
Zhonghua Gan Zang Bing Za Zhi; 2010 Jan; 18(1):75-7. PubMed ID: 20128981
[No Abstract] [Full Text] [Related]
12. Failure of combination therapy with lamivudine and famciclovir following lamivudine monotherapy for hepatitis B virus infection in patients coinfected with human immunodeficiency virus-1.
Matthews GV; Pillay D; Cane P; Ratcliffe D; Gazzard B; Nelson M
Clin Infect Dis; 2001 Dec; 33(12):2049-54. PubMed ID: 11698987
[TBL] [Abstract][Full Text] [Related]
13. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
[TBL] [Abstract][Full Text] [Related]
14. Lamivudine plus tenofovir versus lamivudine plus adefovir for the treatment of hepatitis B virus in HIV-coinfected patients, starting antiretroviral therapy.
Sarkar J; Saha D; Bandyopadhyay B; Saha B; Chakravarty R; Guha SK
Indian J Med Microbiol; 2018; 36(2):217-223. PubMed ID: 30084414
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B core-related antigen assay is useful for monitoring the antiviral effects of nucleoside analogue therapy.
Tanaka E; Matsumoto A; Yoshizawa K; Maki N
Intervirology; 2008; 51 Suppl 1():3-6. PubMed ID: 18544941
[TBL] [Abstract][Full Text] [Related]
16. Outcome of lamivudine resistant hepatitis B virus mutant post-liver transplantation on lamivudine monoprophylaxis.
Chan HL; Chui AK; Lau WY; Chan FK; Hui AY; Rao AR; Wong J; Lai EC; Sung JJ
Clin Transplant; 2004 Jun; 18(3):295-300. PubMed ID: 15142051
[TBL] [Abstract][Full Text] [Related]
17. Lamivudine-resistant HBV infection in HIV-positive patients receiving antiretroviral therapy in a public routine clinic in Cameroon.
Kouanfack C; Aghokeng AF; Mondain AM; Bourgeois A; Kenfack A; Mpoudi-Ngolé E; Ducos J; Delaporte E; Laurent C
Antivir Ther; 2012; 17(2):321-6. PubMed ID: 22290198
[TBL] [Abstract][Full Text] [Related]
18. Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation.
Van Bömmel F; Schernick A; Hopf U; Berg T
Gastroenterology; 2003 Feb; 124(2):586-7. PubMed ID: 12557178
[No Abstract] [Full Text] [Related]
19. The effect of lamivudine on the replication of hepatitis B virus in HIV-infected patients depends on the host immune status (CD4 cell count).
Haverkamp M; Smit M; Weersink A; Boucher CA; Hoepelman AI
AIDS; 2003 Jul; 17(10):1572-4. PubMed ID: 12824802
[TBL] [Abstract][Full Text] [Related]
20. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients.
Benhamou Y; Bochet M; Thibault V; Di Martino V; Caumes E; Bricaire F; Opolon P; Katlama C; Poynard T
Hepatology; 1999 Nov; 30(5):1302-6. PubMed ID: 10534354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
